Nerviano Medical Sciences

The largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.
Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Novel JAK2 inhibitors discovered by Nerviano Medical Sciences featured on the cover of Bioorganic & Medicinal Chemistry Nerviano - Italy, September 2014- Nerviano Medical Sciences researchers report the discovery, structure guided design, synthesis and biological evaluation of a novel class of JAK2 inhibitors on the journal Bioorganic & Medicinal Chemistry (“Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors”; Read more
Nerviano Medical Sciences' partner Ignyta announces interim data from RXDX-101 phase I clinical trial at 2014 ESMO congress Nerviano, Italy – September 29, 2014 - Nerviano Medical Sciences’ partner Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, presented interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101 in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain. Ignyta reports... Read more
Two young researchers of Nerviano Medical Sciences winners of the award “Premio Società Italiana di Farmacologia- Farmindustria per Ricerche Farmacologiche” 2014 September 17, 2014 - Nerviano, Italy. Congratulations to Daniela Asa and Fabio Gasparri, scientists at Nerviano Medical Sciences in the Biotechnology and Cell Biology Departments, respectively, for winning the prize of the “Società Italiana di Farmacologia (SIF)- Farmindustria per Ricerche Farmacologiche” 2014.The prize, intended to reinforce the scientific research and partnering between... Read more


Nerviano Medical SciencesWe fight cancer. Our mission is to identify innovative agents for clinical development in areas of unmet



Nerviano Medical SciencesCLIOSS operates as your partner in the clinical development and life-cycle management



AcceleraAccelera is committed to predicting and managing potential toxic, pharmacokinetic



NerpharmaNerPharMa is a leading player in high-containment contract